Literature DB >> 18487063

Hematopoiesis in mice is extremely resilient to wide variation in TIMP/MMP balance.

Peter Haviernik1, Maria T Diaz, Eleonora Haviernikova, William Tse, William G Stetler-Stevenson, Kevin D Bunting.   

Abstract

Tissue inhibitors of matrix metalloproteinases (TIMPs) are natural inhibitors of matrix metalloproteinases (MMPs) and are associated with normal and pathologic extracellular matrix turnover. Because the microenvironment is critical for normal hematopoietic stem/progenitor cell function, we aimed to determine whether alterations in the TIMP/MMP balance impact upon normal hematopoiesis in mice. We have used both overexpression and knockout mouse models to determine whether early hematopoiesis is susceptible to potentially pathologic changes in TIMP/MMP level. These studies used TIMP-1(-/-) mice and retroviral vectors co-expressing human TIMP-1 or TIMP-2 linked with the green fluorescent protein (GFP) transduced into bone marrow (BM) cells and transplanted into lethally-irradiated recipient mice. Loss of TIMP-1 in knockout mice or retroviral overexpression of TIMP-1 or TIMP-2 did not alter hematopoietic stem/progenitor function during steady-state hematopoiesis. Surprisingly, even when applying hematopoietic stress through mobilization, chemotaxis, or myelosuppression, murine hematopoiesis was not adversely affected by TIMP-1 or TIMP-2 level. We conclude that TIMP/MMP balance alone does not exert significant influence on blood cell development and homeostasis. An important corollary of these studies is that specific modulation using MMP inhibitors for cancer or immunologic therapy is unlikely to have adverse hematopoietic side effects.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18487063      PMCID: PMC2600540          DOI: 10.1016/j.bcmd.2008.03.005

Source DB:  PubMed          Journal:  Blood Cells Mol Dis        ISSN: 1079-9796            Impact factor:   3.039


  45 in total

1.  Identification of CD63 as a tissue inhibitor of metalloproteinase-1 interacting cell surface protein.

Authors:  Ki-Kyung Jung; Xu-Wen Liu; Rosemarie Chirco; Rafael Fridman; Hyeong-Reh Choi Kim
Journal:  EMBO J       Date:  2006-08-17       Impact factor: 11.598

2.  Altered tumor growth and metastasis of a T-cell lymphoma in Timp-1 transgenic mice.

Authors:  A Krüger; J E Fata; R Khokha
Journal:  Blood       Date:  1997-09-01       Impact factor: 22.113

3.  Regulation of matrix metalloproteinase-9 (MMP-9) in TNF-stimulated neutrophils: novel pathways for tertiary granule release.

Authors:  Subhadeep Chakrabarti; Jennifer M Zee; Kamala D Patel
Journal:  J Leukoc Biol       Date:  2005-11-07       Impact factor: 4.962

4.  Mobilization by either cyclophosphamide or granulocyte colony-stimulating factor transforms the bone marrow into a highly proteolytic environment.

Authors:  Jean Pierre Lévesque; Jean Hendy; Yasushi Takamatsu; Brenda Williams; Ingrid G Winkler; Paul J Simmons
Journal:  Exp Hematol       Date:  2002-05       Impact factor: 3.084

5.  Adenoviral delivery of TIMP1 or TIMP2 can modify the invasive behavior of pancreatic cancer and can have a significant antitumor effect in vivo.

Authors:  A S Rigg; N R Lemoine
Journal:  Cancer Gene Ther       Date:  2001-11       Impact factor: 5.987

6.  Targeted mutagenesis of Timp-1 reveals that lung tumor invasion is influenced by Timp-1 genotype of the tumor but not by that of the host.

Authors:  P D Soloway; C M Alexander; Z Werb; R Jaenisch
Journal:  Oncogene       Date:  1996-12-05       Impact factor: 9.867

7.  TIMP-2 mediated inhibition of angiogenesis: an MMP-independent mechanism.

Authors:  Dong-Wan Seo; Hongmei Li; Liliana Guedez; Paul T Wingfield; Tere Diaz; Rita Salloum; Bei-yang Wei; William G Stetler-Stevenson
Journal:  Cell       Date:  2003-07-25       Impact factor: 41.582

8.  Inhibition of metastasis in human gastric cancer cells transfected with tissue inhibitor of metalloproteinase 1 gene in nude mice.

Authors:  M Watanabe; Y Takahashi; T Ohta; M Mai; T Sasaki; M Seiki
Journal:  Cancer       Date:  1996-04-15       Impact factor: 6.860

9.  Overexpression of metalloproteinase inhibitor in B16F10 cells does not affect extravasation but reduces tumor growth.

Authors:  S Koop; R Khokha; E E Schmidt; I C MacDonald; V L Morris; A F Chambers; A C Groom
Journal:  Cancer Res       Date:  1994-09-01       Impact factor: 12.701

10.  Long-term exposure to elevated levels of circulating TIMP-1 but not mammary TIMP-1 suppresses growth of mammary carcinomas in transgenic mice.

Authors:  Masaharu Yamazaki; Takemi Akahane; Todd Buck; Hitoshi Yoshiji; Daniel E Gomez; Daniel J Schoeffner; Eijiro Okajima; Steven R Harris; Opal R Bunce; Snorri S Thorgeirsson; Unnur P Thorgeirsson
Journal:  Carcinogenesis       Date:  2004-05-27       Impact factor: 4.944

View more
  2 in total

1.  TIMP-1 deficiency subverts cell-cycle dynamics in murine long-term HSCs.

Authors:  Lara Rossi; Aysegul V Ergen; Margaret A Goodell
Journal:  Blood       Date:  2011-04-26       Impact factor: 22.113

2.  Tissue inhibitor of metalloproteinase-3 (TIMP-3) regulates hematopoiesis and bone formation in vivo.

Authors:  Yi Shen; Ingrid G Winkler; Valerie Barbier; Natalie A Sims; Jean Hendy; Jean-Pierre Lévesque
Journal:  PLoS One       Date:  2010-09-30       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.